Tachyon is accelerating innovative science to develop first-in-class therapeutics against significant new drug targets in cancer biology. Tachyon operates with a dedicated internal core development team and a world-class external network of expertise to achieve one goal - advance our programs with speed, innovation, quality and scientific integrity.
Location: United States, California, San Francisco
Employees: 1-10
Total raised: $11.6M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 29.06.2023 | Red Tree V... | redtreevc.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.02.2023 | Series A | $11.6M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 08.10.2021 | Tachyon Presents TACH101 Data at the 2021 AACR-NCI-EORTC Con... | Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a research and developm... | marketscre... |
| 17.09.2021 | Tachyon Announces Presentation at the 2021 ESMO Annual Meeti... | Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a research and developm... | marketscre... |
| 04.06.2021 | Tachyon Announces Presentations at the ASCO Annual Meeting | Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a research and developm... | marketscre... |
| - | Tachyon Therapeutics | “We are advancing novel, highly selective first-in-class compounds to improve the treatment of cance... | fastfounde... |